Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 13,478 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glargine, Insulin Glulisine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Digital Health Coaching, Food Box Delivery, Remote Patient Monitoring (RPM), Diabetes Education Class; Behavioral · Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetes Mellitus, Type 2
Interventions: Exenatide once weekly suspension, Exenatide twice daily; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 58
States / cities: Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more

Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions: Biomarker LPA and HE4; Diagnostic Test
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: 18F-AV-133; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypothyroidism
Interventions: Levothyroxine; Drug
Lead sponsor: Jocelyne Karam; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Vorinostat, Carboplatin, Gemcitabine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: PreDiabetes
Interventions: Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 12 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Donislecel (allogeneic islets of Langerhans for transplant); Biological
Lead sponsor: CellTrans Inc.; Industry
Eligibility: 18 Years to 75 Years
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Abnormal Glucose Tolerance, Type 1 Diabetes
Interventions: CTLA4-Ig (Abatacept), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 45 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 16
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 12 more

Conditions: Diabetes Mellitus
Interventions: Education for diabetes self-management; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm; Combination Product
Lead sponsor: Ascendis Pharma Bone Diseases A/S; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Greeley, Colorado • Chicago, Illinois • Minneota, Minnesota + 6 more

Conditions: Diabetes Mellitus
Interventions: cell phone delivered tele-educational, cell phone; Device
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type 2 Diabetes
Interventions: Produce Gift Card and Dietary Education, Usual Care; Behavioral · Other
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia
Interventions: CGM-Tele-monitoring; Other
Lead sponsor: University of Southern California; Other
Eligibility: 65 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • Charlestown, Massachusetts • Columbus, Ohio

Conditions: Hypoglycemia Unawareness, Type 1 Diabetes, Healthy
Interventions: RT-CGM; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 25 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Ovarian Cancer
Interventions: Gleevec/Paclitaxel; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod; Drug · Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: Foundation for the National Institutes of Health; Other
Eligibility: 30 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 1 Diabetes
Interventions: Co-transplantation of PTG with pancreatic islets; Combination Product
Lead sponsor: Peter Stock; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation; Drug
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypoglycemia
Interventions: Naltrexone High Dose, Naltrexone Low Dose; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

Food Delivery, Remote Monitoring, and Coaching-Enhanced Education for Optimized Diabetes Management (FREEDOM)

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Mechanisms for Activation of Beige Adipose Tissue in Humans

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

Community Diabetes Education Program Evaluation "Code Evaluation"

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus

Cardiometabolic Impact of a Produce Prescription Program in Patients With Type 2 Diabetes and Food Insecurity

Telemedicine Monitoring of Nocturnal Incidents

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Glucose Counterregulation in Long Standing Type 1 Diabetes

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia